Duolac Care

Duolac Care Mechanism of Action

Manufacturer:

Cell Biotech

Distributor:

DCH Auriga
Full Prescribing Info
Action
Pharmacology: Pharmacodynamics: Clinical Experience: DUOLAC Care was studied in a randomized, double-blind, placebo-controlled trial in patient with Irritable Bowel Syndrome (IBS). Subjects received either multispecies probiotics (B. longum, B. bifidum, B. lactis, L. acidophilus, L. rhamnosus and S. thermophilus) or a placebo for a period of four weeks.
Results show reduction in Global IBS Relief in subjects who received DUOLAC was significantly higher than those who received placebo (68.0% vs 37.5%, p<0.05).
Improvements in abdominal pain or discomfort and bloating occurred in the probiotics group but in the placebo group.
Fecal analysis revealed that B. lactis (p<0.01), L. rhamnosus (p<0.01) and S. thermophilus (p=0.04) had increased significantly in the DUOLAC group after four weeks.
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $139 a year.
Sign up for free
Already a member? Sign in